This CPB has been revised to state that NovoSeven RT (rFVIIa) is considered medically necessary for members with severe factor XI deficiency who have developed a factor XI inhibitor. This CPB is revised to specify that Novoeight, Hemofil M, Koate DVI, Monoclate-P, Humate-P, and Alphanate are considered medically necessary for hemophilia A when criteria are met, and that AlphanineSD and Mononine are considered medically necessary for hemophilia B when criteria are met. This CPB is revised to state that Profilnine is considered medically necessary for factor II deficiency when criteria are met. This CPB is updated to note that Bebulin has been withdrawn from the market. This CPB has been revised to state that factor XIII concentrate [Human] (Corifact) is considered medically necessary for the prevention of bleeding and for the peri-operative management of surgical bleeding in persons with acquired factor XIII deficiency. (The previous version of the CPB limited coverage of Corifact to persons with congenital factor XIII deficiency.).